drugset / Trial / NCT03976050
Phase I Study of HL-085 in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
The study drug, HL-085 is a MEK inhibitor with the potential indication for cancers. It is an oral medication to be given daily. The purposes of this study is to find answers to the following research questions: 1. What is the highest tolerable dose of HL-085 that can be given to subjects when given orally (by mouth) on a twice daily basis? 2. What are the side effects of HL-085? 3. How much HL-085 is in the blood at specific times after dosing and how does the body get rid of the HL-085?
Timeline
- Start
- 2019-06-17
- Primary completion
- 2020-11-12
- Completion
- 2020-11-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tunlametinib | Small molecule | 6 mg | Oral |
| Subject | Tunlametinib | Small molecule | 9 mg | Oral |
| Subject | Tunlametinib | Small molecule | 12 mg | Oral |
| Subject | Tunlametinib | Small molecule | 18 mg | Oral |